Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2007

View Archived Issues

Takeda looks back on FY2006

Positive preclinical results with combined anthrax and plague vaccine

Clinical studies of drugs for digestive diseases

New therapeutic options for cancer imparted in recent patents

Recent Schering and Vertex patents describe novel therapeutic agents for respiratory disorders

Recent GSK patent discloses novel agents targeting hepatitis C virus infection

Clinical data on lisdexamfetamine in ADHD detailed

Pooled data show efficacy and safety of agomelatine in major depressive disorder

Recent clinical trials in urological cancer

LCP-Tacro delivers higher bioavailability compared to Prograf

First-in-class GABA-enhanced antipsychotic safe and well-tolerated in phase I study

Improved efficacy of PhGalpha1 demonstrated in new preclinical studies

NICE recommends use of Champix on U.K.'s National Health Service

Orlistat GSK recommended for approval in E.U.

XMT-1001 begins phase I study in solid tumors

Novacea and Schering-Plough sign license agreement for Asentar

CeNeRx licenses rights to PharmaNess cannabinoid portfolio

LymphoStat-B begins second phase III trial for SLE

XL-647 studied in new phase II NSCLC trial

Canadian approval for Thelin

Vernakalant (iv) filed in Canada

Aeras Global TB Vaccine Foundation updates TB vaccine development progress

Twice-daily Zyflo CR receives FDA approval

Vantas progresses through E.U. mutual recognition procedure

FDA approves new formulation of FazaClo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...